The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series
Abstract
Background: A limited number of published case reports suggest a positive effect of dextroamphetamine, an adrenergic agonist affecting both the central nervous system (CNS) and peripheral nervous system, on physical activity and weight in patients with hypothalamic obesity (intractable obesity following CNS insult). Here, we present our clinical experience with dextroamphetamine treatment for hypothalamic obesity. Methods: The clinical course of all patients started on dextroamphetamine treatment for severe hypothalamic obesity at our institution between 2010 and 2013 is reported. Dextroamphetamine administration was initiated at a single dose of 5 mg per day and titrated to effect up to a dose of 20 mg/day. BMI z-score velocity was calculated as change in BMI z-score over standardized intervals of 12 months. Parameters of treatment success and adverse events were assessed in a standardized fashion. Results: Seven patients (2 males; mean age 17.6 years [range 12.9–24.5]) underwent individual treatment attempts with dextroamphetamine between 2010 and 2013. The primary diagnoses were craniopharyngioma (n = 4), ganglioglioma WHO I (n = 1), astrocytoma (n = 1), and neonatal meningitis (n = 1). Time from initial CNS insult to initiation of dextroamphetamine treatment averaged 5.2 years (range 2.4 months to 16.5 years). All patients demonstrated a steady increase in BMI z-score from the time of initial diagnosis until initiation of dextroamphetamine treatment. Mean baseline BMI z-score was +3.17 ± 0.93 (+1.9 to +4.4). Mean BMI z-score velocity decelerated to –0.18 ± 0.12 per year during the first year of treatment and stabilized at +0.05 ± 0.32 per year during the second year of treatment. No significant adverse events were reported. Conclusion: Dextroamphetamine treatment led to stabilization or reduction of BMI z-score in a cohort of 7 patients with hypothalamic obesity, with no adverse effects. Considering the projected increase in BMI z-score according to the natural course of the disease, these findings are promising and warrant further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several central stimulants have been used off label for the treatment of hypothalamic obesity such as methylphenidate, phentermine, dextroamphetamine, mazindol, caffeine, and ephedrine (121, 122, 137-139), but data on these drugs are based on small studies with mixed results.”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [121]
In the citing paper
“In 2 small case series, dexamphetamines were reported to reduce BMI, increase REE, and improve energy level in children with hypothalamic obesity (121, 122).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [121]
In the citing paper
“Reports of other types of stimulant use in individuals with hypothalamic obesity such as amphetamines have generally demonstrated weight loss or attenuation of weight gain (121, 122, 143, 146).”
From Management of Acquired Hypothalamic Dysfunction and the Hypothalamic Syndrome; It Is More Than Obesity (2025) · cites this paper as [121]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leone, T. C., Lehman, J. J., Finck, B. N., Schaeffer, P. J., Wende, A. R., Boudina, S., Courtois, M., Wozniak, D. F., Sambandam, N., Bernal-Mizrachi, C., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030101 · Cited by 951
Wilens, T. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318173312f · Cited by 269
Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity
Roth, C. L., Eslamy, H., Werny, D., Elfers, C., Shaffer, M. L., Pihoker, C., Ojemann, J., & Dobyns, W. B. (2015) · Obesity · doi:10.1002/oby.21067 · Cited by 96
Research works printed but not linked: 19
- 10.1111/j.1467-789X.2012.01004.x · DOI
- 10.3389/fendo.2011.00060 · DOI · Paper page
- 10.1515/jpem-2014-0512 · DOI
- 10.1038/nrendo.2010.168 · DOI
- 10.1210/jc.2003-031751 · DOI · Paper page
- 10.3390/jcm4091774 · DOI
- 10.1203/pdr.0b013e3180332cd6 · DOI · Paper page
- 10.1097/CHI.0b013e31817e0ea7 · DOI
- 10.1111/ijcp.12771 · DOI
- 10.1515/JPEM.2006.19.2.129 · DOI
- 10.1001/archpedi.156.9.887 · DOI · Paper page
- 10.1007/s001120170107 · DOI · Paper page
- 10.1136/adc.27.131.10 · DOI
- 10.1530/EJE-12-1082 · DOI
- 10.1146/annurev.pa.33.040193.003231 · DOI · Paper page
- 10.1113/jphysiol.2008.165464 · DOI
- 10.1016/j.neuroscience.2005.03.023 · DOI
- 10.3389/fendo.2011.00078 · DOI · Paper page
- 10.1007/s00431-003-1376-7 · DOI
Cited by
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity
Huynh, K., Klose, M., Krogsgaard, K., Drejer, J., Byberg, S., Madsbad, S., Magkos, F., Aharaz, A., Edsberg, B., Tfelt-Hansen, J., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-0972 · Cited by 43
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
Dextroamphetamine Treatment in Children With Hypothalamic Obesity
van Schaik, J., Welling, M. S., de Groot, C. J., van Eck, J. P., Juriaans, A., Burghard, M., Oude Ophuis, S. B. J., Bakker, B., Tissing, W. J. E., Schouten-van Meeteren, A. Y. N., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.845937 · Cited by 30
Treatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
A Survey of Patient-Relevant Outcomes in Pediatric Craniopharyngioma: Focus on Hypothalamic Obesity
Craven, M., Crowley, J. H., Chiang, L., Kline, C., Malbari, F., Hocking, M. C., & McCormack, S. E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.876770 · Cited by 21
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity
Horne, V. E., Bielamowicz, K., Nguyen, J., Hilsenbeck, S., Lindsay, H., Sonabend, R., Wood, A. C., Okcu, F., & Sisley, S. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28379 · Cited by 20
Sleep Disturbances in Pediatric Craniopharyngioma: A Systematic Review
Cordani, R., Veneruso, M., Napoli, F., Di Iorgi, N., Milanaccio, C., Consales, A., Disma, N., De Grandis, E., Maghnie, M., & Nobili, L. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.876011 · Cited by 15
Multidisciplinary Approach for Hypothalamic Obesity in Children and Adolescents: A Preliminary Study
Tessaris, D., Matarazzo, P., Tuli, G., Tuscano, A., Rabbone, I., Spinardi, A., Lezo, A., Fenocchio, G., Buganza, R., & de Sanctis, L. (2021) · Children · doi:10.3390/children8070531 · Cited by 11
Metadata
- Authors
- Denzer, C., Denzer, F., Lennerz, B. S., Vollbach, H., Lustig, R. H., & Wabitsch, M.
- Venue
- Obesity Facts
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 12
- Issue
- 1
- Pages
- 91-102
- ISSN
- 1662-4025
- 1662-4033
- Cited by
- 55
- References
- 3
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
